Dapiglutide

What It Is

Dapiglutide (development code ZP7570; Zealand Pharma) is an investigational long-acting peptide designed to activate two related gut hormone receptors at once: the glucagon-like peptide-1 (GLP-1) receptor and the glucagon-like peptide-2 (GLP-2) receptor. GLP-1 activation is the mechanism behind the modern obesity and diabetes drugs (semaglutide, tirzepatide and others), reducing appetite, slowing gastric emptying and improving glycemic control. GLP-2 is a sister hormone released from the same intestinal L-cells; it is trophic to the gut lining and underpins approved short-bowel-syndrome drugs such as teduglutide, glepaglutide and apraglutide. Zealand's thesis for dapiglutide was that adding GLP-2 activity to a potent GLP-1 backbone could not only drive weight loss but also strengthen the intestinal barrier and dampen the low-grade systemic inflammation that accompanies obesity and its comorbidities. The molecule is given as a once-weekly subcutaneous injection with stepwise dose escalation. Clinically, dapiglutide produced a mixed record. A first-in-obesity Phase 2a proof-of-concept trial (NCT05788601), published in the Lancet journal eClinicalMedicine in February 2026, randomized 54 adults with obesity to dapiglutide 4 mg, 6 mg or placebo for 12 weeks; the drug was safe and well tolerated but did not achieve statistically significant weight loss versus placebo at those relatively low doses. Zealand then pushed to higher doses in a Phase 1b multiple-ascending-dose program: a 13-week cohort reported about 8.3% mean weight loss, and a 28-week cohort escalating up to 26 mg once weekly reported a mean 11.6% body-weight reduction versus 0.2% for placebo (topline June 2025; data presented at the American Diabetes Association's 85th Scientific Sessions), with gastrointestinal side effects consistent with other incretin therapies. Despite that dose-dependent signal, in November 2025 Zealand announced it was pausing dapiglutide's development as part of active portfolio management: management concluded that an 11.6% result, while real, did not clearly differentiate the drug from newer incretin-based therapies in an increasingly crowded metabolic field, and that advancing it would demand a long, costly clinical path. The company stated the decision reflected competitive positioning rather than any safety concern, and redirected resources toward its more differentiated candidates, the amylin analog petrelintide and the GLP-1/glucagon dual agonist survodutide. Dapiglutide is not approved for any use and is not available as a compounding-pharmacy 'research peptide'; it remains a clinical-stage biologic-class molecule whose chief scientific interest is its dual gut-hormone, barrier-and-inflammation mechanism.

Regulatory Status

Why Researchers Study It

Dapiglutide is studied as a test of whether combining GLP-1 and GLP-2 receptor agonism in a single once-weekly peptide can do more than GLP-1 alone — pairing appetite suppression and weight loss with GLP-2's trophic effects on the intestinal lining to strengthen the gut barrier and reduce the chronic low-grade inflammation ('metabolic endotoxemia') tied to obesity, type 2 diabetes and inflammatory bowel conditions. Even though the program was paused for competitive rather than safety reasons, dapiglutide is a useful case study in dual-incretin design, in how dose escalation converts a placebo-level Phase 2a result into a double-digit weight-loss signal, and in the strategic bar a new obesity peptide must clear to differentiate itself from semaglutide, tirzepatide and next-generation agents. Its GLP-2 arm also keeps interest alive in gut-barrier and anti-inflammatory applications of dual agonists beyond weight loss.

Proposed Mechanisms

• Long-acting peptide that simultaneously activates the GLP-1 receptor and the GLP-2 receptor (dual incretin-family agonism)
• GLP-1 receptor activation reduces appetite, slows gastric emptying and improves glycemic control, driving weight loss (the mechanism shared with semaglutide and tirzepatide)
• GLP-2 receptor activation is trophic to the intestinal mucosa and is intended to improve intestinal barrier ('gut barrier') integrity
• Improved barrier function is hypothesized to lower translocation of bacterial products and reduce obesity-related low-grade systemic inflammation
• Engineered for once-weekly subcutaneous dosing with stepwise dose escalation to manage gastrointestinal tolerability
• Dose-dependent efficacy: minimal separation from placebo at 4-6 mg (Phase 2a) but ~8.3% (13 weeks) and ~11.6% (28 weeks) mean weight loss at higher doses up to 26 mg (Phase 1b)

Evidence Snapshot

Commonly Discussed Benefits

Safety & Cautions

Comparisons

See how Dapiglutide compares to related peptides:

Calculator Tools

Use our research tools to explore dosing and reconstitution data:

Citations

1. [1] Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial — eClinicalMedicine (2026) PubMed
2. [2] Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide (June 2025) PubMed
3. [3] Dapiglutide (program paused) — Zealand Pharma pipeline PubMed
4. [4] Zealand hits pause on dual GLP-1/GLP-2 asset as CMO cites 'increasingly crowded' metabolic development scene — Fierce Biotech PubMed
5. [5] Study Details: NCT05788601 — Dapiglutide for the Treatment of Obesity — ClinicalTrials.gov PubMed

Related Peptides